Catalyst Pharmaceutical Partners Inc. (CPRX) Upgraded to Overweight at Piper Jaffray Cos.
Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) was upgraded by stock analysts at Piper Jaffray Cos. from a “neutral” rating to an “overweight” rating in a research report issued on Wednesday. The brokerage currently has a $4.00 target price on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s price target indicates a potential upside of 173.97% from the stock’s current price.
CPRX has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating on shares of Catalyst Pharmaceutical Partners in a research report on Tuesday, June 14th. Zacks Investment Research raised shares of Catalyst Pharmaceutical Partners from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a research report on Tuesday, June 21st. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $3.56.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) opened at 1.46 on Wednesday. The firm has a 50-day moving average of $1.06 and a 200-day moving average of $0.88. The stock’s market cap is $120.99 million. Catalyst Pharmaceutical Partners has a 12-month low of $0.51 and a 12-month high of $3.55.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. Equities analysts predict that Catalyst Pharmaceutical Partners will post ($0.25) earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada purchased a new position in Catalyst Pharmaceutical Partners during the second quarter worth approximately $117,000. Oxford Asset Management raised its stake in shares of Catalyst Pharmaceutical Partners by 3.5% in the second quarter. Oxford Asset Management now owns 180,721 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 6,140 shares during the period. DRW Securities LLC bought a new stake in shares of Catalyst Pharmaceutical Partners during the second quarter worth about $168,000. Paloma Partners Management Co bought a new stake in shares of Catalyst Pharmaceutical Partners during the second quarter worth about $200,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Catalyst Pharmaceutical Partners during the first quarter worth about $206,000. 30.64% of the stock is currently owned by institutional investors and hedge funds.
Catalyst Pharmaceutical Partners Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Stock Ratings for Catalyst Pharmaceutical Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceutical Partners Inc. and related stocks with our FREE daily email newsletter.